Astec LifeSciences Toekomstige groei

Future criteriumcontroles 5/6

Astec LifeSciences zal naar verwachting groeien in winst en omzet met respectievelijk 100.8% en 32.9% per jaar. De winst per aandeel zal naar verwachting groeien met 100.9% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 18.2% zijn.

Belangrijke informatie

100.8%

Groei van de winst

100.9%

Groei van de winst per aandeel

Chemicals winstgroei	23.0%
Inkomstengroei	32.9%
Toekomstig rendement op eigen vermogen	18.2%
Dekking van analisten	Low
Laatst bijgewerkt	04 Nov 2024

Recente toekomstige groei-updates

Recent updates

Shareholders May Be Wary Of Increasing Astec LifeSciences Limited's (NSE:ASTEC) CEO Compensation Package

Jul 23

Market Participants Recognise Astec LifeSciences Limited's (NSE:ASTEC) Revenues Pushing Shares 28% Higher

Jul 03

Astec LifeSciences Limited (NSE:ASTEC) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable

Mar 15

Astec LifeSciences (NSE:ASTEC) Could Be Struggling To Allocate Capital

May 17

Shareholders Are Optimistic That Astec LifeSciences (NSE:ASTEC) Will Multiply In Value

Oct 14

We Ran A Stock Scan For Earnings Growth And Astec LifeSciences (NSE:ASTEC) Passed With Ease

Jul 27

Here's Why Astec LifeSciences (NSE:ASTEC) Can Manage Its Debt Responsibly

Jun 28

A Look At The Intrinsic Value Of Astec LifeSciences Limited (NSE:ASTEC)

Jun 03

Analysts Just Published A Bright New Outlook For Astec LifeSciences Limited's (NSE:ASTEC)

May 08

Astec LifeSciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 06

Why We Like The Returns At Astec LifeSciences (NSE:ASTEC)

Jan 25

Is Astec LifeSciences (NSE:ASTEC) A Risky Investment?

Dec 13

We Take A Look At Why Astec LifeSciences Limited's (NSE:ASTEC) CEO Has Earned Their Pay Packet

Jul 21

Does Astec LifeSciences (NSE:ASTEC) Have A Healthy Balance Sheet?

May 02

The Trend Of High Returns At Astec LifeSciences (NSE:ASTEC) Has Us Very Interested

Apr 17

Do Astec LifeSciences's (NSE:ASTEC) Earnings Warrant Your Attention?

Apr 02

Is Astec LifeSciences Limited's (NSE:ASTEC) Shareholder Ownership Skewed Towards Insiders?

Mar 18

Declining Stock and Solid Fundamentals: Is The Market Wrong About Astec LifeSciences Limited (NSE:ASTEC)?

Jan 28

What Does Astec LifeSciences Limited's (NSE:ASTEC) Share Price Indicate?

Jan 17

Why We Like The Returns At Astec LifeSciences (NSE:ASTEC)

Jan 08

I Ran A Stock Scan For Earnings Growth And Astec LifeSciences (NSE:ASTEC) Passed With Ease

Dec 28

Is Astec LifeSciences Limited (NSE:ASTEC) Popular Amongst Insiders?

Dec 18

Winst- en omzetgroeiprognoses

NSEI:ASTEC - Toekomstschattingen van analisten en financiële gegevens uit het verleden (INR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
3/31/2027	9,575	933	252	964	2
3/31/2026	7,857	636	162	773	2
3/31/2025	6,242	-711	-136	1,183	1
9/30/2024	3,729	-1,036	-422	119	N/A
6/30/2024	3,852	-785	N/A	N/A	N/A
3/31/2024	4,586	-469	-1,253	102	N/A
12/31/2023	4,317	-509	N/A	N/A	N/A
9/30/2023	4,981	-258	-1,580	101	N/A
6/30/2023	5,871	60	N/A	N/A	N/A
3/31/2023	6,285	256	-426	747	N/A
12/31/2022	7,735	736	N/A	N/A	N/A
9/30/2022	8,297	975	-448	351	N/A
6/30/2022	7,325	883	N/A	N/A	N/A
3/31/2022	6,769	899	-804	236	N/A
12/31/2021	5,803	708	N/A	N/A	N/A
9/30/2021	5,230	531	-800	483	N/A
6/30/2021	5,754	619	N/A	N/A	N/A
3/31/2021	5,587	650	-1,107	-82	N/A
12/31/2020	5,698	723	N/A	N/A	N/A
9/30/2020	5,786	774	1,190	1,885	N/A
6/30/2020	5,639	648	N/A	N/A	N/A
3/31/2020	5,287	475	1,231	1,684	N/A
12/31/2019	4,844	291	N/A	N/A	N/A
9/30/2019	4,781	269	-420	32	N/A
6/30/2019	4,507	331	N/A	N/A	N/A
3/31/2019	4,382	357	-375	153	N/A
12/31/2018	4,246	402	N/A	N/A	N/A
9/30/2018	3,781	374	N/A	N/A	N/A
6/30/2018	3,611	325	N/A	N/A	N/A
3/31/2018	3,676	349	N/A	647	N/A
12/31/2017	3,254	212	N/A	N/A	N/A
9/30/2017	3,119	148	N/A	N/A	N/A
6/30/2017	3,008	192	N/A	N/A	N/A
3/31/2017	2,987	191	N/A	192	N/A
12/31/2016	3,167	-29	N/A	N/A	N/A
9/30/2016	2,865	-114	N/A	N/A	N/A
6/30/2016	2,643	-206	N/A	N/A	N/A
3/31/2016	2,330	50	N/A	-125	N/A
12/31/2015	2,629	-115	N/A	N/A	N/A
9/30/2015	2,777	61	N/A	N/A	N/A
6/30/2015	2,728	84	N/A	N/A	N/A
3/31/2015	2,669	148	N/A	75	N/A
12/31/2014	2,212	131	N/A	N/A	N/A
9/30/2014	2,147	127	N/A	N/A	N/A
6/30/2014	2,156	96	N/A	N/A	N/A
3/31/2014	2,070	87	N/A	146	N/A
12/31/2013	2,179	97	N/A	N/A	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat ASTEC de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 6.7% ).

Winst versus markt: Er wordt verwacht dat ASTEC de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat ASTEC binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van ASTEC ( 32.9% per jaar) zal naar verwachting sneller groeien dan de markt Indian ( 10.6% per jaar).

Hoge groei-inkomsten: De omzet van ASTEC ( 32.9% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen ASTEC zal naar verwachting over 3 jaar laag zijn ( 18.2 %).

Ontdek groeibedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2024/12/20 01:58
Aandelenkoers aan het einde van de dag	2024/12/20 00:00
Inkomsten	2024/09/30
Jaarlijkse inkomsten	2024/03/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .

Bronnen van analisten

Astec LifeSciences Limited wordt gevolgd door 8 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
null null	Asian Markets Securities Private Limited
Ankur Periwal	Axis Capital Limited
Satish Kumar	CGS International

Astec LifeSciences Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 14% to ₹1,090

Price target decreased by 14% to ₹1,108

Price target decreased by 9.3% to ₹1,205

Price target decreased to ₹1,923

Price target increased to ₹2,132

Price target increased to ₹1,869

Recent updates

Astec Lifesciences Limited Announces Appointment of Arijit Mukherjee as the Manager

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

Astec Lifesciences Limited Announces Resignation of Brahma Nand Vyas as an Independent Director

Price target decreased by 14% to ₹1,090

Astec Lifesciences Limited Announces Resignation of Anurag Roy as Chief Executive Officer, Effective October 25, 2024

New major risk - Revenue and earnings growth

Insufficient new directors

Shareholders May Be Wary Of Increasing Astec LifeSciences Limited's (NSE:ASTEC) CEO Compensation Package

Astec LifeSciences Limited to Report Q1, 2025 Results on Jul 29, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Market Participants Recognise Astec LifeSciences Limited's (NSE:ASTEC) Revenues Pushing Shares 28% Higher

Astec LifeSciences Limited, Annual General Meeting, Jul 29, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Astec Lifesciences Limited Announces Resignation of Mr. K. Suryanarayan as Chief Financial Officer, Effective May 3, 2024

Astec LifeSciences Limited to Report Q4, 2024 Results on May 02, 2024

Price target decreased by 14% to ₹1,108

Astec LifeSciences Limited (NSE:ASTEC) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable

Price target decreased by 9.3% to ₹1,205

Third quarter 2024 earnings released: ₹12.41 loss per share (vs ₹0.43 profit in 3Q 2023)

Astec LifeSciences Limited to Report Q3, 2024 Results on Jan 25, 2024

Second quarter 2024 earnings released: ₹6.85 loss per share (vs ₹9.34 profit in 2Q 2023)

Astec LifeSciences Limited to Report Q2, 2024 Results on Oct 27, 2023

Astec LifeSciences Limited Declares Final Dividend for the Financial Year Ended March 31, 2023

Astec LifeSciences Limited to Report Q1, 2024 Results on Jul 27, 2023

Upcoming dividend of ₹1.50 per share at 0.1% yield

Full year 2023 earnings released: EPS: ₹13.04 (vs ₹45.87 in FY 2022)

Non-Executive Non-Independent Director recently sold ₹4.8m worth of stock

Astec LifeSciences (NSE:ASTEC) Could Be Struggling To Allocate Capital

Astec LifeSciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023, Payable by August 1, 2023

Full year 2023 earnings released: EPS: ₹13.04 (vs ₹45.87 in FY 2022)

Investor sentiment improves as stock rises 23%

Third quarter 2023 earnings released: EPS: ₹0.43 (vs ₹12.63 in 3Q 2022)

Astec LifeSciences Limited to Report Q3, 2023 Results on Jan 30, 2023

Price target decreased to ₹1,923

High number of new directors

Second quarter 2023 earnings released: EPS: ₹9.34 (vs ₹4.63 in 2Q 2022)

Astec Lifesciences Limited Announces Appointment of Mr. Madhur Gundecha as the Chief Financial Officer

Astec LifeSciences Limited to Report Q2, 2023 Results on Oct 28, 2022

Investor sentiment improved over the past week

Shareholders Are Optimistic That Astec LifeSciences (NSE:ASTEC) Will Multiply In Value

Astec LifeSciences Limited Announces the Resignation of Saurav Bhala as Chief Financial Officer

Price target increased to ₹2,132

High number of new directors

We Ran A Stock Scan For Earnings Growth And Astec LifeSciences (NSE:ASTEC) Passed With Ease

Astec Lifesciences Limited Appoints Burjis Godrej as an Additional, Non-Executive, Non- Independent Director

Astec LifeSciences Limited to Report Q1, 2023 Results on Jul 25, 2022

Upcoming dividend of ₹1.50 per share

Full year 2022 earnings: Revenues exceed analyst expectations

Here's Why Astec LifeSciences (NSE:ASTEC) Can Manage Its Debt Responsibly

A Look At The Intrinsic Value Of Astec LifeSciences Limited (NSE:ASTEC)

Price target increased to ₹1,869

Consensus revenue estimates increase by 11%

Analysts Just Published A Bright New Outlook For Astec LifeSciences Limited's (NSE:ASTEC)

Astec LifeSciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Astec LifeSciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Astec LifeSciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

MD & Director recently bought ₹37m worth of stock

Astec LifeSciences Limited Announces Cessation of Ashok Hiremath as the Managing Director of the Company

Non-Executive Non-Independent Director recently bought ₹1.5m worth of stock

Non-Executive Non-Independent Director recently bought ₹3.5m worth of stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Why We Like The Returns At Astec LifeSciences (NSE:ASTEC)

Insider recently sold ₹1.5m worth of stock

Insider recently sold ₹1.5m worth of stock

Is Astec LifeSciences (NSE:ASTEC) A Risky Investment?

Investor sentiment improved over the past week

Insider recently sold ₹2.4m worth of stock

Price target increased to ₹1,508